Chandrama Mukherjee1,1, Kevin M Sweet2,2, Jasmine A Luzum3,3, Mahmoud Abdel-Rasoul4,4, Michael F Christman5,5, Joseph P Kitzmiller1,6,1,6. 1. Department of Biological Chemistry & Pharmacology, Ohio State University, Columbus, OH 43210, USA. 2. Division of Human Genetics, Ohio State University, Columbus, OH 43210, USA. 3. Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA. 4. Center for Biostatistics, College of Medicine, Ohio State University, 1800 Cannon Drive Columbus, OH 43210, USA. 5. Coriell Institute for Medical Research, Camden, NJ 08103, USA. 6. Center for Pharmacogenomics, College of Medicine, Ohio State University, 5086 Graves Hall, 333 West 10th Avenue Columbus, OH 43210, USA.
Abstract
AIM: This study aimed to examine pharmacogenomic test results and patient perspectives at an academic cardiovascular medicine clinic. PATIENTS & METHODS: Test results for three common cardiovascular drug-gene tests (warfarin-CYP2C9-VKORC1, clopidogrel-CYP2C19 and simvastatin-SLCO1B1) of 208 patients in the Ohio State University-Coriell Personalized Medicine Collaborative were examined to determine the incidence of potentially actionable test results. A post-hoc, anonymous, patient survey was also conducted. RESULTS: Potentially actionable test results for at least one of the three drug-gene tests were determined in 170 (82%) patients. Survey responses (n = 134) suggested that patients generally considered their test results to be important (median of 7.5 on a 10-point scale of importance) and were interested (median of 7.3 on a 10-point scale of interest) in a Clinical Pharmacogenomic Service. CONCLUSION: Attitudes toward pharmacogenomic testing were generally favorable, and potentially actionable test results were not uncommon in this cardiovascular medicine cohort.
AIM: This study aimed to examine pharmacogenomic test results and patient perspectives at an academic cardiovascular medicine clinic. PATIENTS & METHODS: Test results for three common cardiovascular drug-gene tests (warfarin-CYP2C9-VKORC1, clopidogrel-CYP2C19 and simvastatin-SLCO1B1) of 208 patients in the Ohio State University-Coriell Personalized Medicine Collaborative were examined to determine the incidence of potentially actionable test results. A post-hoc, anonymous, patient survey was also conducted. RESULTS: Potentially actionable test results for at least one of the three drug-gene tests were determined in 170 (82%) patients. Survey responses (n = 134) suggested that patients generally considered their test results to be important (median of 7.5 on a 10-point scale of importance) and were interested (median of 7.3 on a 10-point scale of interest) in a Clinical Pharmacogenomic Service. CONCLUSION: Attitudes toward pharmacogenomic testing were generally favorable, and potentially actionable test results were not uncommon in this cardiovascular medicine cohort.
Authors: Noah A Rosenberg; Jonathan K Pritchard; James L Weber; Howard M Cann; Kenneth K Kidd; Lev A Zhivotovsky; Marcus W Feldman Journal: Science Date: 2002-12-20 Impact factor: 47.728
Authors: E J Stanek; C L Sanders; K A Johansen Taber; M Khalid; A Patel; R R Verbrugge; B C Agatep; R E Aubert; R S Epstein; F W Frueh Journal: Clin Pharmacol Ther Date: 2012-01-25 Impact factor: 6.875
Authors: Mattias Jakobsson; Sonja W Scholz; Paul Scheet; J Raphael Gibbs; Jenna M VanLiere; Hon-Chung Fung; Zachary A Szpiech; James H Degnan; Kai Wang; Rita Guerreiro; Jose M Bras; Jennifer C Schymick; Dena G Hernandez; Bryan J Traynor; Javier Simon-Sanchez; Mar Matarin; Angela Britton; Joyce van de Leemput; Ian Rafferty; Maja Bucan; Howard M Cann; John A Hardy; Noah A Rosenberg; Andrew B Singleton Journal: Nature Date: 2008-02-21 Impact factor: 49.962
Authors: Kristine R Crews; Shane J Cross; John N McCormick; Donald K Baker; Alejandro R Molinelli; Richard Mullins; Mary V Relling; James M Hoffman Journal: Am J Health Syst Pharm Date: 2011-01-15 Impact factor: 2.637
Authors: Noah A Rosenberg; Saurabh Mahajan; Sohini Ramachandran; Chengfeng Zhao; Jonathan K Pritchard; Marcus W Feldman Journal: PLoS Genet Date: 2005-12-09 Impact factor: 5.917
Authors: Jason L Vassy; Sojeong Chun; Sanjay Advani; Sophie A Ludin; Jason G Smith; Elaine C Alligood Journal: Clin Pharmacol Ther Date: 2018-10-18 Impact factor: 6.875
Authors: Ann M Moyer; Brian Dukek; Patti Duellman; Brittany Schneider; Laurie Wakefield; Jennifer M Skierka; Rajeswari Avula; Aditya V Bhagwate; Krishna R Kalari; Justin D Kreuter; Matthew P Goetz; Judy C Boughey; John L Black; Manish J Gandhi Journal: Hum Immunol Date: 2020-06-13 Impact factor: 2.850
Authors: Jasmine A Luzum; Natasha Petry; Annette K Taylor; Sara L Van Driest; Henry M Dunnenberger; Larisa H Cavallari Journal: Clin Pharmacol Ther Date: 2021-07-07 Impact factor: 6.903
Authors: Amy C Sturm; Tara Schmidlen; Laura Scheinfeldt; Shelly Hovick; Joseph P McElroy; Amanda E Toland; J Scott Roberts; Kevin Sweet Journal: J Pers Med Date: 2018-07-25